Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
This research evaluates how well furosemide alone compares to furosemide combined with albumin in critically ill adults who have fluid overload. The study aims to find out if adding albumin improves urine output and kidney function markers compared to using furosemide by itself. Key measurements include urine output two hours after treatment, kidney blood flow indicators, and various biochemical tests. Participants are randomly assigned to receive either furosemide at 1 mg per kg of body weight intravenously over 30 minutes with a placebo, or the same dose of furosemide together with 50 grams of 25% albumin infused over 30 minutes. The study uses bedside ultrasound to assess fluid overload signs and monitors blood pressure, electrolytes, and kidney filtration rates during the trial. During the study, participants undergo urine output measurement at two hours and blood tests to track changes in kidney function and electrolyte levels up to 24 hours after treatment. Ultrasound evaluations assess vein size and congestion at baseline and after two hours. Researchers monitor safety and response to treatment while collecting data on urine volume and kidney health markers to understand the impact of adding albumin to furosemide therapy.
Actively Recruiting
Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating two dose levels of mRNA-1283 in children aged 6 months to less than 12 years to find the best dose for each age group. The study is a phase 2, randomized, observer-blind trial comparing mRNA-1283 with mRNA-1273 as an active comparator. It aims to assess safety, immune response, and side effects related to these vaccines against SARS-CoV-2. The study includes two cohorts Cohort 1 involves children aged 2 to less than 12 years receiving a single intramuscular dose of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. Cohort 2 includes children aged 6 months to less than 2 years who are unvaccinated against COVID-19 and receive two intramuscular doses 28 days apart of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. The study compares the immune responses and side effects between these groups. Participants will be monitored for local and systemic adverse reactions for 7 days after vaccination and unsolicited adverse events for up to 28 days. Serious and medically attended adverse events will be tracked throughout the study, which lasts up to 13 months. Researchers will measure antibody levels against SARS-CoV-2 at specific visits to evaluate immune response. The trial includes regular medical evaluations and safety assessments to ensure participant well-being.
Actively Recruiting
Researchers are studying children with heart failure caused by left ventricular systolic dysfunction LVSD, a condition where the heart cannot pump enough blood. The goal is to see if the drug finerenone, which blocks a protein related to inflammation and scarring, can help the heart pump better compared to a placebo. This is the first study to test finerenone specifically in children with heart failure and LVSD, focusing on safety and effects on heart stress markers. Participants aged 6 months to under 18 years will be randomly assigned to receive either finerenone or a placebo for about three months, alongside their regular heart failure treatments. After this period, those who qualify may join an additional nine-month open-label phase where all receive finerenone. Those who do not join the extension will have a follow-up visit one month after finishing treatment. During the study, participants will visit the clinic at least three times for physical exams, heart tests including ECG and echocardiogram, blood tests, and measurements like blood pressure and heart rate. Researchers will track changes in a heart stress protein called NT-proBNP, monitor safety by recording any adverse events, and measure other heart function markers. The total study duration can be up to about a year including the extension and follow-up.
Actively Recruiting
Researchers are evaluating the use of oscillometry and fractional exhaled nitric oxide FeNO testing in primary care to diagnose asthma and chronic obstructive pulmonary disease COPD. The study compares these methods to specialist-based diagnosis, aiming to address challenges with spirometry, such as patient effort, technical difficulties, and reproducibility, which affect diagnostic accuracy especially in primary care settings. This observational study is conducted across 7 countries in the Middle East, Africa, Asia, and Latin America at hospital sites, focusing on patients with suspected asthma or COPD. Primary care physicians are trained to use oscillometry and FeNO testing following international guidelines, using tools like the Ambulatory Lung Diagnosis System. Patients suspected of asthma or COPD undergo symptom questionnaires and primary care assessment with these tests. If specialist diagnosis cannot be done same day, it occurs within three days. There are no follow-up visits planned. The study aims to assess the technical feasibility and diagnostic accuracy of these tools in routine primary care compared to specialist diagnosis. Participants provide consent, complete history and symptom questionnaires, and undergo oscillometry and FeNO testing at primary care sites. Diagnostic accuracy is measured by comparing primary care results to specialist diagnoses using statistical metrics like Cohens kappa, sensitivity, and specificity within 1 to 3 days. No additional follow-up or long-term monitoring is planned. The studys findings will help determine if these methods can improve early and accurate diagnosis of asthma and COPD in primary care.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of levosulpiride in improving eye problems caused by diabetic macular edema DME and diabetic retinopathy DR. These conditions are leading causes of vision loss in adults with diabetes, and current treatments like laser therapy or anti-angiogenic drugs have limitations and risks. This study explores a new approach by raising prolactin hormone levels using levosulpiride, aiming to protect the retina and reduce disease progression. Participants with different stages of diabetic eye disease will be randomly assigned to receive either levosulpiride or a placebo pill taken orally three times a day. Some groups include patients undergoing vitrectomy surgery or receiving standard anti-angiogenic treatment with ranibizumab levosulpiride or placebo is given alongside these therapies. Treatment durations vary from one week to 24 weeks depending on the group, always combined with regular diabetes and blood pressure management. During the study, participants will undergo detailed eye exams including imaging tests like optical coherence tomography and fundus photography, blood tests to measure prolactin and other markers, and vision assessments. Researchers will monitor retinal changes, visual acuity, and hormone levels to assess treatment effects. Safety and adherence will be carefully tracked throughout the study period, which extends up to several months. The trial also involves thorough data collection and quality control to ensure reliable results.
Actively Recruiting
Researchers are investigating the effects of high-frequency repetitive transcranial magnetic stimulation rTMS on improving executive functions in adults with Alcohol Use Disorder AUD who are currently abstinent. AUD can cause lasting changes in brain function and behavior, including difficulties with cognitive flexibility, which may contribute to relapse. This study aims to assess both short- and long-term clinical and cognitive outcomes, as well as brain changes, in this population. Participants will receive daily rTMS treatment targeted to the left dorsolateral prefrontal cortex lDLPFC at 10 Hz frequency, with two sessions per day over 20 business days for four weeks. The location of stimulation is personalized using an algorithm based on brain connectivity. There is also a comparison group receiving sham stimulation with the coil placed on the vertex, following the same schedule and intensity. During the study, participants will undergo cognitive testing and brain imaging at baseline, after the 4-week treatment, and at 6-month follow-up to measure changes in executive functions and brain connectivity. Clinical outcomes, including alcohol craving and symptoms of anxiety and depression, will be monitored throughout. The study lasts about six months from baseline to final follow-up, with safety and treatment adherence carefully observed.
Actively Recruiting
This research aims to evaluate the effects of immediate postoperative bevacizumab administration in patients with proliferative diabetic retinopathy undergoing vitrectomy surgery. The study focuses on individuals with type I or II diabetes who require surgery to address complications such as non-clearing vitreous hemorrhage, tractional retinal detachment, or fibrovascular proliferation affecting vision. The goal is to compare outcomes between those who receive bevacizumab right after surgery and those who do not. Participants will be randomly assigned to one of two groups one group will receive an injection of bevacizumab immediately after their vitrectomy, while the other group will not receive this treatment. The surgery involved is pars plana vitrectomy, performed to improve vision affected by the diabetic eye complications. This is a double-blind study, meaning neither the participants nor the researchers know who receives the drug or not during the trial. During the study, participants will be followed and assessed for six months after surgery. Researchers will monitor their vision using tests such as the best-corrected spectacle visual acuity on the Snellen chart. They will also evaluate the safety and effectiveness of the treatment, looking for any changes or complications. Participants will attend scheduled visits to support ongoing monitoring and outcome measurement over this period.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
1-10 of 16
1